ER and PR positive means that breast cancer cells have proteins on their surface called estrogen receptors (ER) and progesterone receptors (PR) that respond to hormones. About 70% of breast cancers are hormone receptor-positive, and this designation directly shapes which treatments work best. It’s generally considered a favorable finding because these cancers respond to therapies that block or lower hormone levels.
How Hormone Receptors Fuel Cancer Growth
In normal breast tissue, estrogen and progesterone help regulate cell growth and function. They work by attaching to receptor proteins inside cells, which then switch on genes that tell cells to grow and divide. When breast cancer develops, the cancer cells can keep these receptors and exploit them. Estrogen binds to ER, triggering signals that drive cancer cell growth. Progesterone binds to PR, which further amplifies the growth signal and can also help cancer cells evade the immune system.
PR expression actually depends on estrogen activity. The estrogen receptor switches on the gene that produces progesterone receptors, so when a tumor is both ER and PR positive, it signals that the estrogen-driven pathway is active and functioning. This is important because it means the cancer is heavily reliant on hormones, making it a good target for hormone-blocking treatments.
How Receptors Are Tested
After a biopsy or surgery, a pathologist examines the tumor tissue under a microscope using a staining technique called immunohistochemistry. The tissue is treated with chemicals that attach to hormone receptors and change color, making them visible. The pathologist then counts how many cancer cells stain positive and how intensely they stain.
Guidelines from the American Society of Clinical Oncology and the College of American Pathologists define ER or PR as positive when 1% or more of tumor cell nuclei stain positive. In practice, pathologists often break results into more specific categories: less than 1% (negative), 1% to 9% (low positive), and 10% or more (strongly positive). Many labs report results using the Allred score, which combines the percentage of positive cells with staining intensity on a scale from 0 to 8. A score of 3 or higher is considered positive, though scores in the lower range (corresponding to roughly 1% to 10% positive cells) fall into an “uncertain benefit” category where hormone therapy may be recommended but its advantage is less clear.
Why PR Status Matters Alongside ER
Not all hormone receptor-positive cancers behave the same way. Being ER positive and PR positive together is the most favorable combination. When a tumor is ER positive but PR negative, outcomes are measurably worse. A large meta-analysis found that patients with ER-positive, PR-negative disease had a 57% higher risk of their cancer returning compared to those whose tumors were positive for both receptors. Overall survival followed the same pattern, with a 69% higher risk of death in the ER-positive, PR-negative group.
The likely reason: PR negativity in an ER-positive tumor suggests that the estrogen signaling pathway isn’t functioning in the typical way, which can mean the cancer is less dependent on hormones alone and may be driven by additional growth signals. This distinction can influence how aggressively doctors approach treatment.
Survival Rates for Hormone Receptor-Positive Cancer
Hormone receptor-positive breast cancers generally carry better survival statistics than hormone receptor-negative types. The 10-year overall survival rate for ER-positive breast cancer is approximately 80%, compared to about 69% for ER-negative disease. In the first five years after diagnosis, women with ER-negative tumors face significantly higher mortality. Interestingly, if a woman with ER-negative cancer survives past the 10-year mark, her ongoing risk actually drops below that of ER-positive patients, whose recurrence risk persists at a low but steady rate for many years.
This long tail of recurrence risk is one reason hormone therapy for ER/PR-positive cancers sometimes extends well beyond the initial treatment period.
How Hormone Receptor-Positive Cancer Is Treated
The core strategy is straightforward: if the cancer needs hormones to grow, cut off the hormone supply or block the receptors. There are two main approaches.
The first uses medications called selective estrogen receptor modulators, which physically sit in the estrogen receptor and prevent estrogen from activating it. Tamoxifen is the most well-known and can be used by both premenopausal and postmenopausal women. The second approach uses aromatase inhibitors, which stop the body from producing estrogen in the first place by blocking the enzyme responsible for making it. These are primarily used in postmenopausal women. Premenopausal women can take them, but only in combination with a medication that suppresses ovarian function, since active ovaries produce too much of the enzyme for the inhibitors to work alone.
The standard course of hormone therapy is five years, which has been shown to significantly reduce recurrence. Five years of treatment cut the 10-year recurrence rate from roughly 38% to about 25% in hormone receptor-positive patients. For women at higher risk, particularly those who are postmenopausal or have cancer that has spread to lymph nodes, extending treatment to 10 years offers additional benefit. Premenopausal women appear to gain less from extended therapy based on current evidence.
Common Side Effects
Tamoxifen commonly causes hot flashes, vaginal discharge, menstrual irregularities, sexual dysfunction, and carries a small increased risk of blood clots. Because it acts like estrogen in some tissues, it can also stimulate changes in the uterine lining, including polyps and, rarely, uterine tumors. Aromatase inhibitors have a different side effect profile: joint pain and stiffness are very common, along with loss of bone density over time and sexual dysfunction. These side effects are manageable for most women, but they’re worth discussing with a treatment team since they can significantly affect quality of life over years of therapy.
When HER2 Is Also Positive
Some ER/PR-positive cancers also test positive for a third marker called HER2, a protein that promotes aggressive cell growth. This combination, sometimes called triple-positive breast cancer, presents a unique challenge. The estrogen and HER2 signaling pathways talk to each other inside the cell. When treatment blocks one pathway, the other can compensate and ramp up, leading to drug resistance. For this reason, triple-positive cancers typically require a combination strategy targeting both the hormone receptors and HER2 simultaneously, often pairing hormone therapy with HER2-targeted therapy and additional medications that interrupt cell growth signals.
What Your Pathology Report Means in Practice
If your report says ER-positive and PR-positive, it tells you several things at once. Your cancer belongs to the most common subtype, you have effective targeted treatment options available, and your statistical outlook is among the more favorable for breast cancer. The specific percentage of positive cells matters too. A tumor where 90% of cells stain positive is more hormone-dependent, and likely more responsive to hormone therapy, than one where only 3% stain positive.
Your receptor status will also be considered alongside other factors like tumor size, grade, lymph node involvement, and HER2 status to build a complete picture. Together, these details guide decisions about whether you need chemotherapy in addition to hormone therapy, how long your treatment should last, and how closely you should be monitored in the years that follow.